Literature DB >> 12850309

Cytotoxic T lymphocyte antigen-4 gene (CTLA4) polymorphisms in Japanese patients with psoriasis vulgaris.

Yuichiro Tsunemi, Hidehisa Saeki, Megumi Kishimoto, Hiroshi Mitsui, Yayoi Tada, Hideshi Torii, Mayumi Komine, Akihiko Asahina, Kunihiko Tamaki, Takashi Sekiya.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12850309     DOI: 10.1016/s0923-1811(03)00104-x

Source DB:  PubMed          Journal:  J Dermatol Sci        ISSN: 0923-1811            Impact factor:   4.563


× No keyword cloud information.
  5 in total

Review 1.  The Potential Role of Inhibitory Receptors in the Treatment of Psoriasis.

Authors:  Neha Shah; Sabina Sandigursky; Adam Mor
Journal:  Bull Hosp Jt Dis (2013)       Date:  2017-05

Review 2.  [Molecular genetic basis of predisposition to psoriasis].

Authors:  E S Galimova; V L Akhmetova; E K Khusnutdinova
Journal:  Genetika       Date:  2008-05

3.  Cytotoxic T lymphocyte antigen-4 promoter -658CT gene polymorphism is associated with ulcerative colitis in Chinese patients.

Authors:  Yan Luo; Bing Xia; Chun Li; Zhitao Chen; Liuqing Ge; Ting Jiang; Feng Zhou; Yan Zhao
Journal:  Int J Colorectal Dis       Date:  2008-12-16       Impact factor: 2.571

4.  Association of Cytotoxic T Lymphocyte Antigen-4 Gene Polymorphisms with Psoriasis Vulgaris: A Case-Control Study in Turkish Population.

Authors:  Hatice Gül Dursun; Hüseyin Osman Yılmaz; Recep Dursun; Sevsen Kulaksızoğlu
Journal:  J Immunol Res       Date:  2018-04-23       Impact factor: 4.818

Review 5.  The role of regulatory T cells and genes involved in their differentiation in pathogenesis of selected inflammatory and neoplastic skin diseases. Part III: Polymorphisms of genes involved in Tregs' activation and function.

Authors:  Bogusław Nedoszytko; Małgorzata Sokołowska-Wojdyło; Joanna Renke; Magdalena Lange; Piotr Trzonkowski; Michał Sobjanek; Aneta Szczerkowska-Dobosz; Marek Niedoszytko; Aleksandra Górska; Jan Romantowski; Jarosław Skokowski; Leszek Kalinowski; Roman J Nowicki
Journal:  Postepy Dermatol Alergol       Date:  2017-12-31       Impact factor: 1.837

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.